Results 181 to 190 of about 1,055,467 (319)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer. [PDF]

NPJ Breast Cancer
Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, Curigliano G, Dawood S, Fasching PA, Gerratana L, Giordano A, Ignatiadis M, Iwata H, Janni W, Lim E, Kalinsky K, Ma CX, Mayer EL, Medford AJ, Mouabbi JA, O'Shaughnessy J, Park YH, Pascual J, Razavi P, Sammons S, Sandoval JL, Sisca L, Tarantino P, Wander SA, Werutsky G, Turner NA.   +31 more
europepmc   +1 more source

Therapeutics Letter 3

, 1994
Therapeutics Letter 3 discusses treatment of gastroesophageal reflux disease (GERD). GERD symptoms should be treated with antacids or H2-blockers as much as possible. In refractory cases omeprazole is effective.
Therapeutics Initiative (University of British Columbia)
core  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Editorial: Translational research in the diagnosis and development of therapeutics for peritoneal surface malignancies

Frontiers in Oncology, 2023
Claramae Shulyn Chia, Claramae Shulyn Chia, Claramae Shulyn Chia, Claramae Shulyn Chia, Yan Li, Wim Ceelen, Chin-Ann Johnny Ong, Chin-Ann Johnny Ong, Chin-Ann Johnny Ong, Chin-Ann Johnny Ong, Chin-Ann Johnny Ong, Chin-Ann Johnny Ong   +11 more
doaj   +1 more source

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. [PDF]

ESMO Open
Im SA, Kalinsky K, Jhaveri KL, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan AA, Ciruelos EM, Chung CF, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D.   +19 more
europepmc   +1 more source

Therapeutics Letter 73

, 2009
Therapeutics Letter 73 summarizes the evidence for atomoxetine for Attention-Deficit/Hypertactivity Disorder (ADHD) in children and adolescents. Conclusions: Short-term use (1 year): No RCTs are available.
Therapeutics Initiative (University of British Columbia)
core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Peters S, Piha-Paul SA, Sehgal K, Calvo E, Bockorny B, Galvao V, Dowlati A, Fontana E, Hernandez-Guerrero T, Rivera Herrero F, Kingsley E, Lopez JS, Patnaik A, Perez CA, Sanborn RE, Knowles S, Patilea-Vrana G, Li J, Wang T, Wang Y, Hollebecque A.   +20 more
europepmc   +1 more source

Therapeutics Letter 18

, 1997
Therapeutics Letter 18 considers the management of anxiety disorders in primary care using evidence from systematic reviews. Conclusions: More and better clinical trials are needed to identify the best possible ways to treat anxiety disorders.
Therapeutics Initiative (University of British Columbia)
core